Propanc Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
SCHEDULE 13G/A: Ionic Ventures Exits Propanc Biopharma Stake
Ionic Ventures, LLC and its affiliates have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than 5% of Propanc Biopharma, Inc.'s common stock.
NASDAQ
Ionic Ventures, along with Ionic Management, Brendan O'Neil, and Keith Coulston, has disclosed a 9.9% beneficial ownership stake in Propanc Biopharma, Inc. through a Schedule 13G filing.